4 Healthcare Stock Stories for Tuesday Wellness

Hyperion Therapeutics (HPTX) Closing price $19.07

The firm reports that the FDA has okayed Ravicti for the treatment of urea cycle disorders  in patients two years of age and older. The medication should be commercially available by the end of April.


Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

Celldex Therapeutics (NASDAQ:CLDX) Current price $7.60

Celldex is offering $75,000,000 worth of its common stock in a proposed underwritten public offering. All shares will be sold by the firm. This offering is dependent upon market conditions, so there can be no assurance as to whether or when the offering may be finished, or as to its actual magnitude or terms. The shares will be issued pursuant to a prospectus supplement filed as part of a shelf registration statement previously filed with the Securities and Exchange Commission on Form S-3.



Rockwell Medical (NASDAQ:RMTI): Current price $5.74

Rockwell has reported successful topline results from the PRIME clinical study of Soluble Ferric Pyrophosphate, which is its investigational iron-delivery drug currently in Phase 3 clinical studies for the treatment of iron deficiency in hemodialysis patients. The PRIME study indicated that regular administration of SFP-iron via dialysate decreased the usage of erythropoietin stimulating agents during hemodialysis by 37.1 percent while maintaining iron balance and maximizing iron delivery. Rockwell Medical is a fully-integrated biopharmaceutical firm aiming at end-stage renal disease and chronic kidney disease with innovative products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis.


Delcath Systems (NASDAQ:DCTH): Current price $1.67

The firm announced Monday that the German federal reimbursement agency, Institut für das Entgeltsystem im Krankenhaus, has set up a reimbursement pathway for the treatment of patients suffering from liver metastases with the Delcath Hepatic Chemosat Delivery System for melphalan hydrochloride. The decision by the Institut followed an endorsement by the German Radiology Association, which led 47 cancer centers across Germany to submit applications under the Neue Untersuchungs- und Behandlungsmethoden scheme for new tech reimbursement at specific hospitals. The Value 4 status given to the procedure, while not requiring reimbursement, allows participating cancer centers to negotiate reimbursement coverage for the Chemosat procedure with all insurers serving their region.


Don’t Miss: Will Gilead Continue to Deliver Steady Returns?